Bepotastine Besilate

Cat. No.: HY-A0015  
CAS No.: 190786-44-8  
Molecular Formula: C₂₇H₃₁ClN₂O₆S  
Molecular Weight: 547.06  
Target: Histamine Receptor  
Pathway: GPCR/G Protein; Immunology/Inflammation  
Storage:  
- Powder: -20°C 3 years, 4°C 2 years  
- In solvent: -80°C 6 months, -20°C 1 month  

Solvent & Solubility

In Vitro: 10 mM in DMSO  

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Mass (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration</td>
<td>1 mg</td>
</tr>
<tr>
<td>1 mM</td>
<td>1.8280 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.3656 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1828 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description: Bepotastine Besilate (Bepreve) is a histamine H1 receptor antagonist. IC50 value: Target: Histamine H1 receptor. Bepotastine Besilate (Bepreve) also suppresses some allergic inflammatory processes such as allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus). Bepotastine Besilate (Bepreve) is useful for allergic conjunctivitis.

REFERENCES


[2]. Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI; for the Bepotastine Besilate Ophthalmic Solutions Study Group. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic con

[3]. Kawakami T, Kimura S, Haga T, Doi R, Kyoya M, Nakagawa K, Soma Y. Health-related quality of life assessed by the effect of bepotastine besilate in

[5]. Kida, Tetsuo; Fujii, Atsuko; Sakai, Osamu; Iemura, Masahito; Atsumi, Ikuyo; Wada, Tomoyuki; Sakaki, Hideyuki. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in i